Sensei biotherapeutics to present new preclinical data at upcoming scientific conferences

Boston, march 06, 2024 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that the company will present preclinical data on its conditionally active immuno-oncology programs at upcoming scientific conferences.
SNSE Ratings Summary
SNSE Quant Ranking